Johnson & Johnson released its Q4 and full-year 2022 earnings on Tuesday, reporting a 25% decline in its Q4 earnings.
The healthcare-products company posted $23.7B in Q4 sales, down 4.4% YoY. The company pointed to fewer vaccine sales. Q4 net income was $3.52B, or $1.33 a share. J&J generated $94.94B in full-year sales, up 1.3% YoY.
- The company posted $17.94B in full-year net earnings, or $6.73 a share, down ~14% YoY.
- J&J’s Consumer Health unit, which includes its Band-Aid brand and Tylenol, earned $3.77B in Q4, up 1% YoY, and $14.95B for the year, down 0.5% YoY.
- J&J plans to spin off its Consumer Health this year and has named the new independent entity Kenvue.
- Its Pharmaceutical unit posted $13.16B in Q4 revenue, down 7.4% YoY, and $52.56B for the year, up 1.7% YoY.
- J&J’s MedTech unit, which includes its medical devices, posted $6.78B in revenue for the quarter, down 1.2% YoY, and $27.43B in revenue for the year, up 1.4% YoY.
